GILD – Gilead Sciences, Inc.
Float Short %
1.86
Margin Of Safety %
-5
Put/Call OI Ratio
0.59
EPS Next Q Diff
-0.49
EPS Last/This Y
7.78
EPS This/Next Y
0.58
Price
149.35
Target Price
139.83
Analyst Recom
1.68
Performance Q
21.44
Relative Volume
1.27
Beta
0.38
Ticker: GILD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-07 | GILD | 124.33 | 0.79 | 0.72 | 170677 |
| 2026-01-08 | GILD | 120.79 | 0.80 | 0.55 | 172846 |
| 2026-01-09 | GILD | 121.12 | 0.80 | 0.23 | 173624 |
| 2026-01-12 | GILD | 122.64 | 0.75 | 0.31 | 174079 |
| 2026-01-13 | GILD | 121.77 | 0.76 | 0.42 | 177222 |
| 2026-01-14 | GILD | 124.1 | 0.77 | 0.46 | 176853 |
| 2026-01-15 | GILD | 121.32 | 0.77 | 1.05 | 177171 |
| 2026-01-16 | GILD | 124.92 | 0.78 | 0.36 | 179323 |
| 2026-01-20 | GILD | 124.16 | 0.60 | 0.94 | 111926 |
| 2026-01-21 | GILD | 129.14 | 0.63 | 0.31 | 119104 |
| 2026-01-22 | GILD | 131.14 | 0.60 | 0.19 | 132928 |
| 2026-01-23 | GILD | 135.59 | 0.57 | 0.24 | 140622 |
| 2026-01-26 | GILD | 138.19 | 0.52 | 0.44 | 134199 |
| 2026-01-27 | GILD | 141 | 0.51 | 0.64 | 137844 |
| 2026-01-28 | GILD | 139.73 | 0.57 | 0.55 | 146023 |
| 2026-01-29 | GILD | 139.53 | 0.58 | 1.33 | 151614 |
| 2026-01-30 | GILD | 142.02 | 0.60 | 0.86 | 154148 |
| 2026-02-02 | GILD | 142.89 | 0.58 | 0.35 | 151706 |
| 2026-02-03 | GILD | 143.28 | 0.59 | 0.59 | 155920 |
| 2026-02-05 | GILD | 149.37 | 0.59 | 0.68 | 160821 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-07 | GILD | 124.33 | -0.5 | 1919.8 | 8.16 |
| 2026-01-08 | GILD | 120.64 | -0.1 | 1308.4 | 8.16 |
| 2026-01-09 | GILD | 121.12 | -0.1 | 1686.3 | 8.16 |
| 2026-01-12 | GILD | 122.61 | -0.7 | 1784.6 | 8.16 |
| 2026-01-13 | GILD | 121.75 | -0.7 | 1566.5 | 8.16 |
| 2026-01-14 | GILD | 124.09 | -1.2 | 1859.5 | 8.16 |
| 2026-01-15 | GILD | 121.30 | -1.2 | 1393.1 | 8.16 |
| 2026-01-16 | GILD | 124.93 | -1.2 | 1984.4 | 8.16 |
| 2026-01-20 | GILD | 124.15 | -1.2 | 1575.9 | 8.16 |
| 2026-01-21 | GILD | 129.12 | -1.2 | 2096.2 | 8.16 |
| 2026-01-22 | GILD | 131.18 | -1.3 | 1825.7 | 8.16 |
| 2026-01-23 | GILD | 135.93 | -1.3 | 1876.8 | 8.16 |
| 2026-01-26 | GILD | 137.79 | -1.5 | 1621.2 | 8.16 |
| 2026-01-27 | GILD | 140.97 | -1.5 | 1727.7 | 8.16 |
| 2026-01-28 | GILD | 139.82 | -1.8 | 1376.4 | 8.16 |
| 2026-01-29 | GILD | 139.55 | -1.8 | 1454.9 | 8.16 |
| 2026-01-30 | GILD | 142.04 | -2.5 | 1668.2 | 8.16 |
| 2026-02-02 | GILD | 142.89 | -2.5 | 1542.2 | 8.16 |
| 2026-02-03 | GILD | 143.27 | -3.9 | 1498.1 | 8.16 |
| 2026-02-04 | GILD | 146.25 | -3.9 | 1881.1 | 8.16 |
| 2026-02-05 | GILD | 149.35 | -3.9 | 1888.5 | 8.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-07 | GILD | -7.55 | 0.03 | 1.75 |
| 2026-01-08 | GILD | -7.55 | 0.03 | 1.75 |
| 2026-01-09 | GILD | -7.55 | 0.03 | 1.75 |
| 2026-01-12 | GILD | -7.57 | 0.02 | 1.75 |
| 2026-01-13 | GILD | -7.55 | 0.02 | 1.87 |
| 2026-01-14 | GILD | -7.55 | 0.02 | 1.87 |
| 2026-01-15 | GILD | -7.55 | 0.02 | 1.87 |
| 2026-01-16 | GILD | -7.39 | 0.02 | 1.87 |
| 2026-01-20 | GILD | -7.40 | -0.38 | 1.87 |
| 2026-01-21 | GILD | -7.57 | -0.38 | 1.87 |
| 2026-01-22 | GILD | -7.57 | -0.38 | 0 |
| 2026-01-23 | GILD | -7.57 | -0.38 | 1.83 |
| 2026-01-26 | GILD | -7.57 | 0.06 | 1.87 |
| 2026-01-27 | GILD | -11.21 | 0.06 | 1.87 |
| 2026-01-28 | GILD | -11.21 | 0.06 | 1.86 |
| 2026-01-29 | GILD | -11.21 | 0.06 | 1.86 |
| 2026-01-30 | GILD | -11.21 | 0.06 | 1.86 |
| 2026-02-02 | GILD | -11.21 | 0.05 | 1.86 |
| 2026-02-03 | GILD | -11.21 | 0.05 | 1.86 |
| 2026-02-04 | GILD | -11.21 | 0.05 | 1.86 |
| 2026-02-05 | GILD | -11.70 | 0.05 | 1.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.47
Avg. EPS Est. Current Quarter
1.89
Avg. EPS Est. Next Quarter
1.98
Insider Transactions
-11.7
Institutional Transactions
0.05
Beta
0.38
Average Sales Estimate Current Quarter
7673
Average Sales Estimate Next Quarter
6943
Fair Value
141.3
Quality Score
95
Growth Score
86
Sentiment Score
92
Actual DrawDown %
-1.8
Max Drawdown 5-Year %
-26.6
Target Price
139.83
P/E
23.14
Forward P/E
17
PEG
0.63
P/S
6.38
P/B
8.61
P/Free Cash Flow
20.23
EPS
6.46
Average EPS Est. Cur. Y
8.16
EPS Next Y. (Est.)
8.74
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
27.91
Relative Volume
1.27
Return on Equity vs Sector %
9.2
Return on Equity vs Industry %
0.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
1888.5
Gilead Sciences, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 17600
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
stock quote shares GILD – Gilead Sciences, Inc. Stock Price stock today
news today GILD – Gilead Sciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GILD – Gilead Sciences, Inc. yahoo finance google finance
stock history GILD – Gilead Sciences, Inc. invest stock market
stock prices GILD premarket after hours
ticker GILD fair value insiders trading